CERO Therapeutics Stock Drops Amid Phase 1 Dose Intensification Concerns

CERO Therapeutics shares are trading lower after announcing dose intensification in its Phase 1 study of CER-1236, raising concerns about potential adverse effects and regulatory hurdles.